Foundayo (Orforglipron) Clinical Data and Adverse Effects
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist that produces dose-dependent weight loss of 7.5-11.2% at 72 weeks in adults with obesity, with the highest dose (17.2 mg) achieving mean weight reduction of 11.2% compared to 2.1% with placebo. 1, 2
Clinical Efficacy Data
Weight Loss Outcomes
The pivotal FDA approval was based on two Phase 3 trials (ATTAIN-1 and ATTAIN-2) involving 4,740 adults treated for 72 weeks 1:
Trial 1 (Obesity without diabetes, N=3,127):
- 5.5 mg once daily: -7.5% weight loss (vs -2.1% placebo)
- 9 mg once daily: -8.4% weight loss
- 17.2 mg once daily: -11.2% weight loss 2
Trial 2 (Obesity with type 2 diabetes, N=1,613):
- 5.5 mg: -5.1% weight loss
- 9 mg: -7.0% weight loss
- 17.2 mg: -9.6% weight loss (vs -2.5% placebo) 3
Clinically Meaningful Weight Loss Thresholds
At the 17.2 mg dose by week 72 2:
- 54.6% achieved ≥10% weight loss (vs 12.9% placebo)
- 36.0% achieved ≥15% weight loss (vs 5.9% placebo)
- 18.4% achieved ≥20% weight loss (vs 2.8% placebo)
Cardiometabolic Benefits
Beyond weight loss, orforglipron significantly improved 1, 2:
- Waist circumference: Reductions of 1.57-6.9 cm depending on dose
- Systolic blood pressure: Significant reductions across all doses
- Lipid profile:
- Total cholesterol: -4.51%
- LDL-C: -5.34%
- Triglycerides: -10.07%
- HDL-C: +2.94% 4
- HbA1c in diabetics: Reductions of 0.76-1.04% 4
Patient Demographics
The trials enrolled diverse populations 1:
- Mean age: 45-57 years (range 18-92 years)
- Mean baseline BMI: 35-37 kg/m²
- 47-64% female
- 60-71% White, 17-28% Asian, 7-9% Black
Adverse Effects Profile
Gastrointestinal Effects (Most Common)
The adverse event profile is dominated by gastrointestinal symptoms that are typically mild-to-moderate and occur primarily during dose escalation 1:
| Adverse Event | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Dyspepsia | 4% | 12% | 16% | 13% |
| Abdominal pain | 7% | 13% | 14% | 14% |
Key clinical point: Of patients reporting GI adverse events, 60% were mild, 36% moderate, and only 4% severe. The incidence decreased substantially after completing dose escalation 1.
Treatment Discontinuation
- Overall discontinuation due to adverse events: 8% with orforglipron (5.5 mg: 6%; 9 mg: 9%; 17.2 mg: 10%) vs 3% with placebo 1
- GI-related discontinuations: 3-6% across orforglipron doses vs 0.7% placebo 1
- The majority (5%) who discontinued did so due to gastrointestinal adverse reactions 1
Serious Adverse Events
Acute Pancreatitis:
- 6 confirmed cases in orforglipron-treated patients (0.14 per 100 patient-years) vs 2 cases in 1 placebo patient (0.04 per 100 patient-years) 1
Acute Kidney Injury:
- 0.2% with orforglipron vs 0.05% with placebo, typically related to volume depletion 1
Acute Gallbladder Disease:
- Cholelithiasis: 1% orforglipron vs 0.7% placebo
- Acute cholecystitis: 0.4% orforglipron vs 0.3% placebo 1
Hypoglycemia (in diabetics):
- Glucose <54 mg/dL: 2% orforglipron vs 0.2% placebo
- 7% in patients taking concomitant sulfonylurea vs 0.5% without sulfonylurea 1
- Only 1 severe hypoglycemia event reported (5.5 mg dose) 1
Cardiovascular Effects
Tachycardia:
- Reported in 3% orforglipron vs 0.9% placebo
- Mean heart rate increase: 4-5 beats/minute vs 0.5 with placebo 1
Hypotension:
- 2% orforglipron vs 0.5% placebo
- 4% in patients on concomitant antihypertensives vs 1% without 1
Other Notable Adverse Events
Hair Loss:
- 5% at 17.2 mg dose (associated with weight reduction)
- More common in females (7%) than males (0.9%) 1
Headache: 8-9% across orforglipron doses vs 7% placebo 1
Fatigue: 6-9% across orforglipron doses vs 4% placebo 1
Hepatic Safety
Orforglipron demonstrated favorable hepatic safety 5:
- Mean reductions in ALT/AST with treatment
- No cases meeting criteria for drug-induced liver injury/Hy's Law
- 6 orforglipron-treated patients (0.1%) had ALT/AST ≥3× ULN and TBIL ≥2× ULN, but all had alternative etiologies 5
Mortality
- 10 deaths reported during trials: 6 with orforglipron, 4 with placebo
- Investigators deemed all deaths unrelated to study treatment except one placebo case and one 12 mg orforglipron case (no treatment-related association reported for the orforglipron case) 3
Critical Prescribing Considerations
Contraindications 1
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy and breastfeeding
- Severe hepatic impairment
Dose Adjustments
- Moderate-severe renal impairment or moderate hepatic impairment: Maximum dose 9 mg once daily
- End-stage renal disease: Not recommended 6
Drug Interactions
Orforglipron delays gastric emptying, affecting oral drug absorption 1:
- Acetaminophen Cmax decreased 28% after first dose (effect diminishes with repeated dosing)
- Monitor patients on medications with narrow therapeutic indices
- Instruct patients to inform providers before surgeries/procedures due to delayed gastric emptying 1
Special Populations
Older adults (≥65 years):
- Similar efficacy to younger patients (weight loss: -7.5% to -13.0% at 72 weeks) 7
- Increased sensitivity to CNS adverse effects; use caution 6
- Safety profile generally consistent with overall population 7
Patients with diabetes:
- Reduce sulfonylurea dose to minimize hypoglycemia risk (7-fold higher risk with concomitant use) 1
- Monitor for diabetic retinopathy complications with rapid glycemic improvement 1
Clinical Positioning
Orforglipron represents the first oral GLP-1 receptor agonist approved for obesity management, offering an alternative to injectable therapies 8. While efficacy appears lower than leading injectable GLP-1 RAs (semaglutide 2.4 mg achieves 14.9% weight loss at 68 weeks 9), the oral route may benefit patients who refuse or cannot tolerate injections 10.
The safety profile is consistent with the GLP-1 receptor agonist class, with predominantly mild-to-moderate gastrointestinal effects that improve after dose escalation 1, 2. Long-term use is necessary as weight regain occurs with discontinuation, similar to other anti-obesity medications 9.